Litcius/Paper detail

Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Eugenio Mercuri, Juan J. Vílchez, Odile Boespflug‐Tanguy, Craig M. Zaidman, Jean K. Mah, Nathalie Goemans, Wolfgang Müller‐Felber, E. Niks, Ulrike Schara‐Schmidt, Enrico Bertini, Giacomo P. Comi, Katherine D Mathews, Laurent Servais, Krista Vandenborne, Jessika Johannsen, Sonia Messina, Stefan Spinty, Laura McAdam, Kathryn Selby, Barry J. Byrne, Chamindra G. Laverty, Kevin Carroll, Giulia Zardi, Sara Cazzaniga, N. Coceani, P. Bettica, Craig M. McDonald, Gyula Acsádi, Giovanni Baranello, Astrid Blaschek, John F. Brandsema, Claudia Brogna, Claudio Bruno, Anne M. Connolly, Imelda J. M. de Groot, Liesbeth De Waele, Erika Finanger, Richard S. Finkel, Teresa Gidaro, M. Guglieri, Amy Harper, Mercedes López Lobato, Marcos Madruga Garrido, Francesca Magri, Georgios Manousakis, Riccardo Masson, Migvis Monduy, Nuria Muelas Gómez, Francina Munell, A. Nascimento, Yoram Nevo, Yann Péréon, H. Phan, Valeria Sansone, Mariacristina Scoto, Dragana Vučinić, Tracey Willis

2024The Lancet Neurology120 citationsDOI

Topics & Concepts

Duchenne muscular dystrophyMedicineMuscular dystrophyPlaceboDystrophinPhysical therapyPediatricsInternal medicineAlternative medicinePathologyMuscle Physiology and DisordersNeurogenetic and Muscular Disorders ResearchSirtuins and Resveratrol in Medicine
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial | Litcius